Hims & Hers Health, Inc. Class A Common Stock (HIMS)

This filing notes that shares were withheld automatically to cover tax obligations from quarterly RSU vesting.

Soleil Boughton retains roughly 339,000 shares and additional derivative securities.

This tax-related withholding was tied to quarterly RSU vesting, not discretionary selling.

Tax withholding drove the disposal of 10,201 shares at $28.15 each, reducing this insider's direct holdings by 5%, though they're still up on a net basis given conversions.

This non-discretionary sale was tied to RSU tax withholding; the insider retains 65,734 direct shares and 428,000 derivative securities, per the filing.

The disposition comes as HIMS stock has declined 38% over the past 12 months.

This non-discretionary tax withholding reduced the CTO of Hims' direct holdings, though he retains roughly 194,000 shares and roughly 2 million derivative securities subject to multi-year vesting.

Stock-based compensation vesting triggered mandatory tax withholding, but Dudum retains about 9.7 million shares worth $272 million.

Subscriber growth accelerated as revenue surged 38% and international expansion took off.

Hims & Hers Health’s second quarter results were driven by strong subscriber growth and a ramp-up in its branded weight loss offerings, yet the market reacte...

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

Hims & Hers topped Q2 revenue estimates and raised guidance, but missed EPS forecasts, posted a wider net loss, and faces an FTC lawsuit, leaving Wall Street cautious with a Hold rating.

Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On...

Hims & Hers Health (NYSE:HIMS) reported second-quarter 2026 revenue of more than $753 million, up nearly 40% from a year earlier, as the telehealth company added 300,000 net new subscribers and ended the period with nearly 3 million subscribers globally. Chief Financial Officer Yemi Okupe said dome

Telehealth company Hims & Hers Health (NYSE:HIMS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 38.2% year on year to $753...

Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market hours. Here’s what to expect. Hims & Hers Heal...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

Hims & Hers Health shares have rallied despite an FTC lawsuit over data sharing and billing practices, as weight-loss drug partnerships and Wall Street's cautious Hold rating shape the stock's outlook ahead of Q2 earnings.

In the past 12 months, the stock has nosedived more than 50%.

Hims & Hers Health and QXO face heavy short interest amid dilution and loss concerns, while KLA has slid nearly 40% since June as AI-driven chip spending fears grip semiconductor stocks.

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...